Infertility Drugs and Devices Market, By Type (Infertility Drugs (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), Infertility Devices (Equipment, Accessories)), By Gender (Male, Female), By R

Infertility Drugs and Devices Market, By Type (Infertility Drugs (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), Infertility Devices (Equipment, Accessories)), By Gender (Male, Female), By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Infertility Drugs and Devices used for treating infertility in male and female. Factors such as endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction. Treatment procedure constitutes of drugs, Assisted Reproductive Technology (ART), surgery, artificial insemination, and in vitro fertilization. Increasing prevalence of erectile dysfunction, increasing research and development, new product approval, and adoption of expansion strategies from major players operating in the market is expected to propel the market growth during the forecast period.
Key features of the study:
This report provides in-depth analysis of the Global Infertility Drugs and Devices market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global Infertility Drugs and Devices market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global Infertility Drugs and Devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Infertility Drugs and Devices market
Detailed Segmentation:
Global Infertility Drugs and Devices Market, By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
Global Infertility Drugs and Devices Market, By Gender:
Male
Female
Global Infertility Drugs and Devices Market, By Region:
North America
By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
By Gender
Male
Female
By Country
U.S.
Canada
Latin America
By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
By Gender
Male
Female
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
By Gender
Male
Female
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
By Gender
Male
Female
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
By Gender
Male
Female
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Type:
Infertility Drugs
Clomiphene citrate
Sex hormones
Gonadotropins
Bromocriptine
Cabergoline
Imipramine
Letrozole
Metformin
Infertility Devices
Equipment
Accessories
By Gender
Male
Female
By Country
North Africa
Central Africa
South Africa
Company Profiles
Apricus Biosciences, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Bayer AG
Cristalia Produtos Quimicos Farmaceuticos Ltda.
Dong-A Pharmaceutical Co. Ltd.
Eli Lilly and Company
Meda Pharmaceuticals, Inc.
Pfizer, Inc.
S.K. Chemicals Co. Ltd.
Vivus, Inc.
Mylan Pharmaceuticals Inc.
Ferring Pharmaceuticals
Cipla Ltd
Aspargo Laboratories, Inc.
Aurobindo Pharma Ltd.
Lupin Limited
Novartis International AG
Daré Bioscience, Inc.
Torrent Pharmaceuticals Ltd.
Alembic Pharmaceuticals
Dr. Reddys Laboratories Ltd
“*” marked represents similar segmentation in other categories in the respective section.